샘플 요청 목록

 카트 문의
시장보고서
상품코드
1880848

세계의 마우스 모델 시장

Mice Model
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 173 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 마우스 모델 시장은 2030년까지 26억 달러에 달할 전망

2024년에 19억 달러로 추정되는 세계의 마우스 모델 시장은 2024년부터 2030년까지의 분석 기간 동안 CAGR 5.3%로 성장하여 2030년까지 26억 달러에 달할 것으로 예측됩니다. 이 보고서에서 분석 대상이 된 부문 중 하나인 CRISPR/Cas9 기술은 6.5%의 CAGR을 기록하며 분석 기간 종료까지 9억 7,670만 달러에 달할 것으로 예측됩니다. 마이크로인젝션 기술 부문의 성장률은 분석 기간 동안 4.3%의 CAGR로 추정됩니다.

미국 시장은 5억 880만 달러로 추정되는 한편 중국은 8.1%의 CAGR로 성장할 것으로 예측됩니다

미국의 마우스 모델 시장은 2024년에 5억 880만 달러로 추정됩니다. 세계 2위 경제 대국인 중국은 2024년부터 2030년까지의 분석 기간 동안 CAGR 8.1%를 기록하며 2030년까지 6억 310만 달러의 시장 규모에 달할 것으로 예측됩니다. 기타 주목할 만한 지역 시장으로는 일본과 캐나다가 있으며, 각각 분석 기간 동안에 CAGR 2.6%, 4.8%로 성장할 것으로 예측됩니다. 유럽에서는 독일이 약 3.2%의 CAGR로 성장할 것으로 예측됩니다.

세계 마우스 모델 시장 - 주요 동향 및 촉진요인 정리

마우스 모델이란 무엇이며, 생물의학 연구에서 왜 중요한가?

마우스 모델은 과학자들이 인간의 질병, 유전학, 약물 반응 등을 연구하기 위해 사용하는 실험용 쥐를 말합니다. 이들 모델은 생쥐가 인간과 많은 생리적, 유전적 유사성을 공유하기 때문에 암, 심장병, 당뇨병, 신경질환 등 다양한 인간 병태생리를 연구하는 데 탁월한 대상이며, 생의학 연구에 필수적인 모델입니다. 마우스 유전체 조작과 유전자 변형 마우스 제작이 가능해짐에 따라 특정 유전자나 질병 과정을 대상으로 한 연구가 가능해졌고, 이러한 모델의 연구 가치가 크게 향상되었습니다. 이러한 능력으로 인해 마우스 모델은 질병 기전 규명, 잠재적 치료 표적 발굴, 신약 및 치료법 평가에 필수적인 도구로 활용되고 있습니다.

유전자 변형은 마우스 모델 연구를 어떻게 발전시키고 있는가?

마우스 모델의 유전자 변형 기술은 보다 정밀하고 표적화된 연구를 가능하게 하여 생의학 연구에 혁명을 일으켰습니다. CRISPR/Cas9 유전자 편집 기술 등의 방법으로 특정 유전자를 녹아웃 또는 변형시킨 마우스를 제작할 수 있게 되어 인간의 유전성 질환이나 병태를 충실하게 재현할 수 있게 되었습니다. 이러한 발전은 연구 개발의 속도를 가속화했을 뿐만 아니라, 마우스 모델이 인간의 건강과 관련된 중요성도 증가시켰습니다. 이러한 기술이 더욱 정교해짐에 따라 복잡한 인간 질병을 마우스로 모델링하는 능력이 향상되어 보다 효과적인 약물 개발, 개발 기간 단축, 그리고 궁극적으로 환자 치료 결과의 개선으로 이어지고 있습니다.

마우스 모델에서 연구자들이 직면한 과제는 무엇인가?

마우스 모델은 널리 사용되고 있지만, 연구자들은 특히 인간 질환의 재현 정확도에 대한 도전에 직면해 있습니다. 마우스와 인간의 면역계, 대사, 생물학적 차이로 인해 질병의 발현 양상이나 치료에 대한 반응이 다를 수 있습니다. 또한, 유전자 조작 마우스의 개발, 유지, 사육에 따른 높은 비용은 특히 고처리량 연구나 자금이 한정된 기관에서 장벽이 될 수 있습니다. 윤리적 고려도 중요한 역할을 합니다. 연구에서의 동물 복지는 윤리 기준과 규제 가이드라인을 준수하기 위해 세심한 주의를 기울여 관리되어야 합니다.

마우스 모델 시장의 성장을 이끄는 요인은 무엇인가?

마우스 모델 시장의 성장은 빠르게 확대되고 있는 유전학 및 맞춤형 의료 분야에서 효과적인 모델의 지속적인 필요성과 같은 여러 요인에 의해 촉진되고 있습니다. 유전공학 및 유전체 편집 기술의 혁신으로 마우스 모델의 연구 응용 범위가 넓어지고, 복잡한 유전적 상호 작용과 질병을 조사하는 데 있어 그 가치가 더욱 높아지고 있습니다. 전 세계적으로 만성질환의 증가와 보다 개인화된 표적치료에 대한 관심도 특수한 마우스 모델에 대한 수요를 자극하고 있습니다. 또한, 제약 분야의 연구개발에 대한 투자 증가와 학계와 생명공학 기업 간의 협력 관계 확대는 마우스 모델의 지속적인 개발 및 개선을 뒷받침하고 있습니다. 새로운 과학적 발전과 규제 요건에 따라 생물의학 환경이 진화하는 가운데, 마우스 모델에 대한 의존도는 앞으로도 계속 유지될 것으로 예상되며, 이 중요한 시장에서 더 많은 혁신과 확장을 촉진할 것으로 보입니다.

부문:

기술(CRISPR/Cas9, 미세주입, 배아줄기세포 주입, 핵이식, 기타 기술), 서비스(번식, 동결보존, 유전자 검사, 검역, 모델 도입 라이선싱, 기타 서비스), 치료 영역(종양학, 중추신경계(CNS), 면역학/염증, 당뇨, 심혈관, 기타 치료 영역)

조사 대상 기업 예시

  • Charles River Laboratories International, Inc.
  • Envigo, Inc.
  • Genoway S.A.
  • Harbour Antibodies BV
  • Horizon Discovery Group PLC
  • inGenious Targeting Laboratory, Inc.
  • Janvier Labs
  • Laboratory Corporation of America Holdings(LabCorp)
  • Taconic Biosciences, Inc.
  • The Jackson Laboratory
  • Trans Genic, Inc.

AI 통합

검증된 전문가 컨텐츠와 AI 툴을 통해 시장 및 경쟁 정보 분석을 혁신하고 있습니다.

Market Glass, Inc.는 LLM이나 산업 특화형 SLM을 쿼리하는 일반적인 방식이 아닌, 전 세계 도메인 전문가들이 엄선한 컨텐츠 리포지토리를 구축했습니다. 여기에는 비디오 전사, 블로그, 검색 엔진 조사, 방대한 양의 기업, 제품/서비스, 시장 데이터 등이 포함됩니다.

관세 영향 계수

Market Glass, Inc.가 본사 소재지, 생산기지, 수출입(완제품 및 OEM)을 기반으로 기업의 경쟁력 변화를 예측하는 가운데, 이번 보고서에서는 지리적 시장에 대한 관세의 영향을 반영하였습니다. 이러한 복잡하고 다면적인 시장 현실은 매출원가(COGS) 증가, 수익성 하락, 공급망 재편 등 경쟁사에게 다양한 영향을 미치며, 미시적 및 거시적 시장 역학에도 영향을 미칩니다.

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트
  • 기타 중동
  • 아프리카

제4장 경쟁

KSM 25.12.11

Global Mice Model Market to Reach US$2.6 Billion by 2030

The global market for Mice Model estimated at US$1.9 Billion in the year 2024, is expected to reach US$2.6 Billion by 2030, growing at a CAGR of 5.3% over the analysis period 2024-2030. CRISPR / CAS9 Technology, one of the segments analyzed in the report, is expected to record a 6.5% CAGR and reach US$976.7 Million by the end of the analysis period. Growth in the Microinjection Technology segment is estimated at 4.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$508.8 Million While China is Forecast to Grow at 8.1% CAGR

The Mice Model market in the U.S. is estimated at US$508.8 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$603.1 Million by the year 2030 trailing a CAGR of 8.1% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.6% and 4.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.2% CAGR.

Global Mice Model Market - Key Trends & Drivers Summarized

What Are Mice Models, and Why Are They Crucial in Biomedical Research?

Mice models are laboratory mice used by scientists to study human diseases, genetics, and drug responses. These models are essential for biomedical research because mice share many physiological and genetic similarities with humans, making them excellent subjects for studying a wide range of human conditions, including cancer, heart disease, diabetes, and neurological disorders. The ability to manipulate the mouse genome and create genetically modified mice has significantly enhanced the value of these models in research, allowing for targeted studies on specific genes or disease processes. This capability makes mice models indispensable tools for understanding disease mechanisms, identifying potential therapeutic targets, and evaluating new drugs and treatments.

How Are Genetic Modifications Advancing Mice Model Research?

Genetic modifications in mice models have revolutionized biomedical research, allowing for more precise and targeted studies. Techniques such as CRISPR/Cas9 gene editing have made it possible to create mice with specific genes knocked out or modified, which can mimic human genetic conditions or diseases closely. These advancements have not only accelerated the pace of research but also improved the relevance of mice models to human health. As these techniques become more refined, they enhance the ability to model complex human diseases in mice, leading to more effective drugs, faster development timelines, and ultimately, better patient outcomes.

What Challenges Do Researchers Face With Mice Models?

Despite their extensive use, researchers face challenges with mice models, particularly concerning the accuracy with which these models replicate human diseases. Differences in mouse and human immune systems, metabolism, and biology can lead to discrepancies in how diseases manifest and respond to treatments in mice versus humans. Additionally, the high costs associated with developing, maintaining, and housing genetically engineered mice can be prohibitive, especially in high-throughput studies or in institutions with limited funding. Ethical considerations also play a significant role, as the welfare of animals in research must be meticulously managed to adhere to ethical standards and regulatory guidelines.

What Drives the Growth in the Mice Model Market?

The growth in the mice model market is driven by several factors, including the ongoing need for effective models in the rapidly expanding fields of genetics and personalized medicine. Innovations in genetic engineering and genome editing technologies have broadened the applications of mice models in research, making them more valuable for studying complex genetic interactions and diseases. The rise in chronic diseases globally and the push for more personalized, targeted therapies have also spurred demand for specialized mice models. Furthermore, the increasing investment in pharmaceutical R&D, coupled with growing collaborations between academic institutions and biotechnology companies, supports the continuous development and refinement of mice models. As the biomedical landscape evolves with new scientific advancements and regulatory requirements, the reliance on mice models is expected to remain strong, driving further innovations and expansions in this vital market.

SCOPE OF STUDY:

The report analyzes the Mice Model market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Technology (CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer, Other Technologies); Service (Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing, Other Services); Therapeutic Area (Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular, Other Therapeutic Areas)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 46 Featured) -

  • Charles River Laboratories International, Inc.
  • Envigo, Inc.
  • Genoway S.A.
  • Harbour Antibodies BV
  • Horizon Discovery Group PLC
  • inGenious Targeting Laboratory, Inc.
  • Janvier Labs
  • Laboratory Corporation of America Holdings (LabCorp)
  • Taconic Biosciences, Inc.
  • The Jackson Laboratory
  • Trans Genic, Inc.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Trade Shocks, Uncertainty, and the Structural Rewiring of the Global Economy
    • How Trump's Tariffs Impact the Market? The Big Question on Everyone's Mind
    • Mice Model - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Biomedical Research Advances Drive Demand for Genetically Modified Mice Models
    • Rising Prevalence of Chronic Diseases Amplifies Need for Effective Mice Models
    • Technological Innovations in Gene Editing Propel Development of Specialized Mice Models
    • Pharmaceutical Industry Focus on Personalized Medicine Boosts Use of Mice Models
    • Advancements in Cancer Research Reliance on Mice Models for Drug Development
    • Ethical and Regulatory Developments Impact Mice Model Use and Care
    • Expansion of Contract Research Organizations (CROs) Increases Availability of Mice Models
    • Educational Institutions Research Needs Support Growth in Mice Model Market
    • Development of Disease-Resistant Mice Models Opens New Research Avenues
    • 3D Printing and Synthetic Biology Impact Mice Model Development
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Mice Model Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Mice Model by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Mice Model by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Mice Model by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for CRISPR / CAS9 by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for CRISPR / CAS9 by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for CRISPR / CAS9 by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Microinjection by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Microinjection by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Microinjection by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Embryonic Stem Cell Injection by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Embryonic Stem Cell Injection by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Embryonic Stem Cell Injection by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Nuclear Transfer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Nuclear Transfer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Nuclear Transfer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Other Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Other Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Other Technologies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Breeding by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Breeding by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Breeding by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Cryopreservation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Cryopreservation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Cryopreservation by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Genetic Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Genetic Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 28: World 15-Year Perspective for Genetic Testing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Quarantine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Quarantine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 31: World 15-Year Perspective for Quarantine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Model-In Licensing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Model-In Licensing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 34: World 15-Year Perspective for Model-In Licensing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 35: World Recent Past, Current & Future Analysis for Other Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 36: World Historic Review for Other Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 37: World 15-Year Perspective for Other Services by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 38: World Recent Past, Current & Future Analysis for Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 39: World Historic Review for Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 40: World 15-Year Perspective for Oncology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 41: World Recent Past, Current & Future Analysis for Central Nervous System (CNS) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 42: World Historic Review for Central Nervous System (CNS) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 43: World 15-Year Perspective for Central Nervous System (CNS) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 44: World Recent Past, Current & Future Analysis for Immunology & Inflammation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 45: World Historic Review for Immunology & Inflammation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 46: World 15-Year Perspective for Immunology & Inflammation by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 47: World Recent Past, Current & Future Analysis for Diabetes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 48: World Historic Review for Diabetes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 49: World 15-Year Perspective for Diabetes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 50: World Recent Past, Current & Future Analysis for Cardiovascular by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 51: World Historic Review for Cardiovascular by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 52: World 15-Year Perspective for Cardiovascular by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 53: World Recent Past, Current & Future Analysis for Other Therapeutic Areas by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 54: World Historic Review for Other Therapeutic Areas by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 55: World 15-Year Perspective for Other Therapeutic Areas by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Mice Model Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 56: USA Recent Past, Current & Future Analysis for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: USA Historic Review for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 58: USA 15-Year Perspective for Mice Model by Technology - Percentage Breakdown of Value Sales for CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 59: USA Recent Past, Current & Future Analysis for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 60: USA Historic Review for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 61: USA 15-Year Perspective for Mice Model by Service - Percentage Breakdown of Value Sales for Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services for the Years 2015, 2025 & 2030
    • TABLE 62: USA Recent Past, Current & Future Analysis for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: USA Historic Review for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 64: USA 15-Year Perspective for Mice Model by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 65: Canada Recent Past, Current & Future Analysis for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Canada Historic Review for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 67: Canada 15-Year Perspective for Mice Model by Technology - Percentage Breakdown of Value Sales for CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 68: Canada Recent Past, Current & Future Analysis for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Canada Historic Review for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 70: Canada 15-Year Perspective for Mice Model by Service - Percentage Breakdown of Value Sales for Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services for the Years 2015, 2025 & 2030
    • TABLE 71: Canada Recent Past, Current & Future Analysis for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Canada Historic Review for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 73: Canada 15-Year Perspective for Mice Model by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas for the Years 2015, 2025 & 2030
  • JAPAN
    • Mice Model Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 74: Japan Recent Past, Current & Future Analysis for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Japan Historic Review for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 76: Japan 15-Year Perspective for Mice Model by Technology - Percentage Breakdown of Value Sales for CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 77: Japan Recent Past, Current & Future Analysis for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Japan Historic Review for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 79: Japan 15-Year Perspective for Mice Model by Service - Percentage Breakdown of Value Sales for Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services for the Years 2015, 2025 & 2030
    • TABLE 80: Japan Recent Past, Current & Future Analysis for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Japan Historic Review for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 82: Japan 15-Year Perspective for Mice Model by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas for the Years 2015, 2025 & 2030
  • CHINA
    • Mice Model Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 83: China Recent Past, Current & Future Analysis for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 84: China Historic Review for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 85: China 15-Year Perspective for Mice Model by Technology - Percentage Breakdown of Value Sales for CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 86: China Recent Past, Current & Future Analysis for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: China Historic Review for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 88: China 15-Year Perspective for Mice Model by Service - Percentage Breakdown of Value Sales for Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services for the Years 2015, 2025 & 2030
    • TABLE 89: China Recent Past, Current & Future Analysis for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 90: China Historic Review for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 91: China 15-Year Perspective for Mice Model by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas for the Years 2015, 2025 & 2030
  • EUROPE
    • Mice Model Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 92: Europe Recent Past, Current & Future Analysis for Mice Model by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 93: Europe Historic Review for Mice Model by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 94: Europe 15-Year Perspective for Mice Model by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 95: Europe Recent Past, Current & Future Analysis for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Europe Historic Review for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 97: Europe 15-Year Perspective for Mice Model by Technology - Percentage Breakdown of Value Sales for CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 98: Europe Recent Past, Current & Future Analysis for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Europe Historic Review for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 100: Europe 15-Year Perspective for Mice Model by Service - Percentage Breakdown of Value Sales for Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services for the Years 2015, 2025 & 2030
    • TABLE 101: Europe Recent Past, Current & Future Analysis for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Europe Historic Review for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 103: Europe 15-Year Perspective for Mice Model by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas for the Years 2015, 2025 & 2030
  • FRANCE
    • Mice Model Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 104: France Recent Past, Current & Future Analysis for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: France Historic Review for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 106: France 15-Year Perspective for Mice Model by Technology - Percentage Breakdown of Value Sales for CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 107: France Recent Past, Current & Future Analysis for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 108: France Historic Review for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 109: France 15-Year Perspective for Mice Model by Service - Percentage Breakdown of Value Sales for Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services for the Years 2015, 2025 & 2030
    • TABLE 110: France Recent Past, Current & Future Analysis for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: France Historic Review for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 112: France 15-Year Perspective for Mice Model by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas for the Years 2015, 2025 & 2030
  • GERMANY
    • Mice Model Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 113: Germany Recent Past, Current & Future Analysis for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Germany Historic Review for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 115: Germany 15-Year Perspective for Mice Model by Technology - Percentage Breakdown of Value Sales for CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 116: Germany Recent Past, Current & Future Analysis for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Germany Historic Review for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 118: Germany 15-Year Perspective for Mice Model by Service - Percentage Breakdown of Value Sales for Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services for the Years 2015, 2025 & 2030
    • TABLE 119: Germany Recent Past, Current & Future Analysis for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Germany Historic Review for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 121: Germany 15-Year Perspective for Mice Model by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 122: Italy Recent Past, Current & Future Analysis for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Italy Historic Review for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 124: Italy 15-Year Perspective for Mice Model by Technology - Percentage Breakdown of Value Sales for CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 125: Italy Recent Past, Current & Future Analysis for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Italy Historic Review for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 127: Italy 15-Year Perspective for Mice Model by Service - Percentage Breakdown of Value Sales for Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services for the Years 2015, 2025 & 2030
    • TABLE 128: Italy Recent Past, Current & Future Analysis for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Italy Historic Review for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 130: Italy 15-Year Perspective for Mice Model by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Mice Model Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 131: UK Recent Past, Current & Future Analysis for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 132: UK Historic Review for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 133: UK 15-Year Perspective for Mice Model by Technology - Percentage Breakdown of Value Sales for CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 134: UK Recent Past, Current & Future Analysis for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 135: UK Historic Review for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 136: UK 15-Year Perspective for Mice Model by Service - Percentage Breakdown of Value Sales for Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services for the Years 2015, 2025 & 2030
    • TABLE 137: UK Recent Past, Current & Future Analysis for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 138: UK Historic Review for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 139: UK 15-Year Perspective for Mice Model by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 140: Spain Recent Past, Current & Future Analysis for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Spain Historic Review for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 142: Spain 15-Year Perspective for Mice Model by Technology - Percentage Breakdown of Value Sales for CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 143: Spain Recent Past, Current & Future Analysis for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Spain Historic Review for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 145: Spain 15-Year Perspective for Mice Model by Service - Percentage Breakdown of Value Sales for Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services for the Years 2015, 2025 & 2030
    • TABLE 146: Spain Recent Past, Current & Future Analysis for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Spain Historic Review for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 148: Spain 15-Year Perspective for Mice Model by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 149: Russia Recent Past, Current & Future Analysis for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Russia Historic Review for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 151: Russia 15-Year Perspective for Mice Model by Technology - Percentage Breakdown of Value Sales for CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 152: Russia Recent Past, Current & Future Analysis for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Russia Historic Review for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 154: Russia 15-Year Perspective for Mice Model by Service - Percentage Breakdown of Value Sales for Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services for the Years 2015, 2025 & 2030
    • TABLE 155: Russia Recent Past, Current & Future Analysis for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Russia Historic Review for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 157: Russia 15-Year Perspective for Mice Model by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 158: Rest of Europe Recent Past, Current & Future Analysis for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Rest of Europe Historic Review for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 160: Rest of Europe 15-Year Perspective for Mice Model by Technology - Percentage Breakdown of Value Sales for CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 161: Rest of Europe Recent Past, Current & Future Analysis for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Rest of Europe Historic Review for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 163: Rest of Europe 15-Year Perspective for Mice Model by Service - Percentage Breakdown of Value Sales for Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services for the Years 2015, 2025 & 2030
    • TABLE 164: Rest of Europe Recent Past, Current & Future Analysis for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Rest of Europe Historic Review for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 166: Rest of Europe 15-Year Perspective for Mice Model by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Mice Model Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 167: Asia-Pacific Recent Past, Current & Future Analysis for Mice Model by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 168: Asia-Pacific Historic Review for Mice Model by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 169: Asia-Pacific 15-Year Perspective for Mice Model by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 170: Asia-Pacific Recent Past, Current & Future Analysis for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Asia-Pacific Historic Review for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 172: Asia-Pacific 15-Year Perspective for Mice Model by Technology - Percentage Breakdown of Value Sales for CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 173: Asia-Pacific Recent Past, Current & Future Analysis for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Asia-Pacific Historic Review for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 175: Asia-Pacific 15-Year Perspective for Mice Model by Service - Percentage Breakdown of Value Sales for Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services for the Years 2015, 2025 & 2030
    • TABLE 176: Asia-Pacific Recent Past, Current & Future Analysis for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Asia-Pacific Historic Review for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 178: Asia-Pacific 15-Year Perspective for Mice Model by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Mice Model Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 179: Australia Recent Past, Current & Future Analysis for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Australia Historic Review for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 181: Australia 15-Year Perspective for Mice Model by Technology - Percentage Breakdown of Value Sales for CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 182: Australia Recent Past, Current & Future Analysis for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Australia Historic Review for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 184: Australia 15-Year Perspective for Mice Model by Service - Percentage Breakdown of Value Sales for Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services for the Years 2015, 2025 & 2030
    • TABLE 185: Australia Recent Past, Current & Future Analysis for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Australia Historic Review for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 187: Australia 15-Year Perspective for Mice Model by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas for the Years 2015, 2025 & 2030
  • INDIA
    • Mice Model Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 188: India Recent Past, Current & Future Analysis for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 189: India Historic Review for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 190: India 15-Year Perspective for Mice Model by Technology - Percentage Breakdown of Value Sales for CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 191: India Recent Past, Current & Future Analysis for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 192: India Historic Review for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 193: India 15-Year Perspective for Mice Model by Service - Percentage Breakdown of Value Sales for Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services for the Years 2015, 2025 & 2030
    • TABLE 194: India Recent Past, Current & Future Analysis for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 195: India Historic Review for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 196: India 15-Year Perspective for Mice Model by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 197: South Korea Recent Past, Current & Future Analysis for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 198: South Korea Historic Review for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 199: South Korea 15-Year Perspective for Mice Model by Technology - Percentage Breakdown of Value Sales for CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 200: South Korea Recent Past, Current & Future Analysis for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 201: South Korea Historic Review for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 202: South Korea 15-Year Perspective for Mice Model by Service - Percentage Breakdown of Value Sales for Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services for the Years 2015, 2025 & 2030
    • TABLE 203: South Korea Recent Past, Current & Future Analysis for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 204: South Korea Historic Review for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 205: South Korea 15-Year Perspective for Mice Model by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 206: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Rest of Asia-Pacific Historic Review for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 208: Rest of Asia-Pacific 15-Year Perspective for Mice Model by Technology - Percentage Breakdown of Value Sales for CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 209: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Rest of Asia-Pacific Historic Review for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 211: Rest of Asia-Pacific 15-Year Perspective for Mice Model by Service - Percentage Breakdown of Value Sales for Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services for the Years 2015, 2025 & 2030
    • TABLE 212: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Rest of Asia-Pacific Historic Review for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 214: Rest of Asia-Pacific 15-Year Perspective for Mice Model by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Mice Model Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 215: Latin America Recent Past, Current & Future Analysis for Mice Model by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 216: Latin America Historic Review for Mice Model by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 217: Latin America 15-Year Perspective for Mice Model by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 218: Latin America Recent Past, Current & Future Analysis for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 219: Latin America Historic Review for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 220: Latin America 15-Year Perspective for Mice Model by Technology - Percentage Breakdown of Value Sales for CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 221: Latin America Recent Past, Current & Future Analysis for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 222: Latin America Historic Review for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 223: Latin America 15-Year Perspective for Mice Model by Service - Percentage Breakdown of Value Sales for Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services for the Years 2015, 2025 & 2030
    • TABLE 224: Latin America Recent Past, Current & Future Analysis for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 225: Latin America Historic Review for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 226: Latin America 15-Year Perspective for Mice Model by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 227: Argentina Recent Past, Current & Future Analysis for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 228: Argentina Historic Review for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 229: Argentina 15-Year Perspective for Mice Model by Technology - Percentage Breakdown of Value Sales for CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 230: Argentina Recent Past, Current & Future Analysis for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 231: Argentina Historic Review for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 232: Argentina 15-Year Perspective for Mice Model by Service - Percentage Breakdown of Value Sales for Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services for the Years 2015, 2025 & 2030
    • TABLE 233: Argentina Recent Past, Current & Future Analysis for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 234: Argentina Historic Review for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 235: Argentina 15-Year Perspective for Mice Model by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 236: Brazil Recent Past, Current & Future Analysis for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 237: Brazil Historic Review for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 238: Brazil 15-Year Perspective for Mice Model by Technology - Percentage Breakdown of Value Sales for CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 239: Brazil Recent Past, Current & Future Analysis for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 240: Brazil Historic Review for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 241: Brazil 15-Year Perspective for Mice Model by Service - Percentage Breakdown of Value Sales for Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services for the Years 2015, 2025 & 2030
    • TABLE 242: Brazil Recent Past, Current & Future Analysis for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 243: Brazil Historic Review for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 244: Brazil 15-Year Perspective for Mice Model by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 245: Mexico Recent Past, Current & Future Analysis for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 246: Mexico Historic Review for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 247: Mexico 15-Year Perspective for Mice Model by Technology - Percentage Breakdown of Value Sales for CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 248: Mexico Recent Past, Current & Future Analysis for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 249: Mexico Historic Review for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 250: Mexico 15-Year Perspective for Mice Model by Service - Percentage Breakdown of Value Sales for Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services for the Years 2015, 2025 & 2030
    • TABLE 251: Mexico Recent Past, Current & Future Analysis for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 252: Mexico Historic Review for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 253: Mexico 15-Year Perspective for Mice Model by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 254: Rest of Latin America Recent Past, Current & Future Analysis for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 255: Rest of Latin America Historic Review for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 256: Rest of Latin America 15-Year Perspective for Mice Model by Technology - Percentage Breakdown of Value Sales for CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 257: Rest of Latin America Recent Past, Current & Future Analysis for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 258: Rest of Latin America Historic Review for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 259: Rest of Latin America 15-Year Perspective for Mice Model by Service - Percentage Breakdown of Value Sales for Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services for the Years 2015, 2025 & 2030
    • TABLE 260: Rest of Latin America Recent Past, Current & Future Analysis for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 261: Rest of Latin America Historic Review for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 262: Rest of Latin America 15-Year Perspective for Mice Model by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Mice Model Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 263: Middle East Recent Past, Current & Future Analysis for Mice Model by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 264: Middle East Historic Review for Mice Model by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 265: Middle East 15-Year Perspective for Mice Model by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 266: Middle East Recent Past, Current & Future Analysis for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 267: Middle East Historic Review for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 268: Middle East 15-Year Perspective for Mice Model by Technology - Percentage Breakdown of Value Sales for CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 269: Middle East Recent Past, Current & Future Analysis for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 270: Middle East Historic Review for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 271: Middle East 15-Year Perspective for Mice Model by Service - Percentage Breakdown of Value Sales for Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services for the Years 2015, 2025 & 2030
    • TABLE 272: Middle East Recent Past, Current & Future Analysis for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 273: Middle East Historic Review for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 274: Middle East 15-Year Perspective for Mice Model by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 275: Iran Recent Past, Current & Future Analysis for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 276: Iran Historic Review for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 277: Iran 15-Year Perspective for Mice Model by Technology - Percentage Breakdown of Value Sales for CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 278: Iran Recent Past, Current & Future Analysis for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 279: Iran Historic Review for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 280: Iran 15-Year Perspective for Mice Model by Service - Percentage Breakdown of Value Sales for Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services for the Years 2015, 2025 & 2030
    • TABLE 281: Iran Recent Past, Current & Future Analysis for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 282: Iran Historic Review for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 283: Iran 15-Year Perspective for Mice Model by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 284: Israel Recent Past, Current & Future Analysis for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 285: Israel Historic Review for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 286: Israel 15-Year Perspective for Mice Model by Technology - Percentage Breakdown of Value Sales for CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 287: Israel Recent Past, Current & Future Analysis for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 288: Israel Historic Review for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 289: Israel 15-Year Perspective for Mice Model by Service - Percentage Breakdown of Value Sales for Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services for the Years 2015, 2025 & 2030
    • TABLE 290: Israel Recent Past, Current & Future Analysis for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 291: Israel Historic Review for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 292: Israel 15-Year Perspective for Mice Model by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 293: Saudi Arabia Recent Past, Current & Future Analysis for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 294: Saudi Arabia Historic Review for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 295: Saudi Arabia 15-Year Perspective for Mice Model by Technology - Percentage Breakdown of Value Sales for CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 296: Saudi Arabia Recent Past, Current & Future Analysis for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 297: Saudi Arabia Historic Review for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 298: Saudi Arabia 15-Year Perspective for Mice Model by Service - Percentage Breakdown of Value Sales for Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services for the Years 2015, 2025 & 2030
    • TABLE 299: Saudi Arabia Recent Past, Current & Future Analysis for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 300: Saudi Arabia Historic Review for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 301: Saudi Arabia 15-Year Perspective for Mice Model by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 302: UAE Recent Past, Current & Future Analysis for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 303: UAE Historic Review for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 304: UAE 15-Year Perspective for Mice Model by Technology - Percentage Breakdown of Value Sales for CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 305: UAE Recent Past, Current & Future Analysis for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 306: UAE Historic Review for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 307: UAE 15-Year Perspective for Mice Model by Service - Percentage Breakdown of Value Sales for Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services for the Years 2015, 2025 & 2030
    • TABLE 308: UAE Recent Past, Current & Future Analysis for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 309: UAE Historic Review for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 310: UAE 15-Year Perspective for Mice Model by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 311: Rest of Middle East Recent Past, Current & Future Analysis for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 312: Rest of Middle East Historic Review for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 313: Rest of Middle East 15-Year Perspective for Mice Model by Technology - Percentage Breakdown of Value Sales for CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 314: Rest of Middle East Recent Past, Current & Future Analysis for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 315: Rest of Middle East Historic Review for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 316: Rest of Middle East 15-Year Perspective for Mice Model by Service - Percentage Breakdown of Value Sales for Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services for the Years 2015, 2025 & 2030
    • TABLE 317: Rest of Middle East Recent Past, Current & Future Analysis for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 318: Rest of Middle East Historic Review for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 319: Rest of Middle East 15-Year Perspective for Mice Model by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas for the Years 2015, 2025 & 2030
  • AFRICA
    • Mice Model Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 320: Africa Recent Past, Current & Future Analysis for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 321: Africa Historic Review for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 322: Africa 15-Year Perspective for Mice Model by Technology - Percentage Breakdown of Value Sales for CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 323: Africa Recent Past, Current & Future Analysis for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 324: Africa Historic Review for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 325: Africa 15-Year Perspective for Mice Model by Service - Percentage Breakdown of Value Sales for Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services for the Years 2015, 2025 & 2030
    • TABLE 326: Africa Recent Past, Current & Future Analysis for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 327: Africa Historic Review for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 328: Africa 15-Year Perspective for Mice Model by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas for the Years 2015, 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제